3-甲氧基乙酰氨基苯 | 3251-55-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 3-甲氧基乙酰氨基苯
• 中文别名: 3-甲氧基乙酰氨基酚
• 英文名称: 3-methoxyacetaminophen
• 英文别名: 3-O-methyl-Acetaminophen；N-(4-hydroxy-3-methoxyphenyl)acetamide
• CAS: 3251-55-6
• 化学式: C₉H₁₁NO₃
• mdl: MFCD00058675
• 分子量: 181.191
• InChiKey: KIZWIAQUWRXFNC-UHFFFAOYSA-N

物化性质

• 熔点：
  118-1220C
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-甲氧基乙酰氨基苯 在 氢氧化钾 、 硫酸 作用下， 生成 4-乙氧基-3-甲氧基苯胺
  参考文献：
  名称：

  Heidelberger; Jacobs, Journal of the American Chemical Society, 1919, vol. 41, p. 1457

  摘要：

  DOI：
• 作为产物：
  描述：

  3-硝基苯甲醚 在 苯基溴化硒 、 rhodium on carbon 、 碳酸氢钠 、 一水合肼 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 为溶剂， 反应 18.0h， 生成 3-甲氧基乙酰氨基苯
  参考文献：
  名称：

  Redox‐Neutral Selenium‐Catalysed Isomerisation of para ‐Hydroxamic Acids into para ‐Aminophenols

  摘要：

  AbstractA selenium‐catalysed para‐hydroxylation of N‐aryl‐hydroxamic acids is reported. Mechanistically, the reaction comprises an N−O bond cleavage and consecutive selenium‐induced [2,3]‐rearrangement to deliver para‐hydroxyaniline derivatives. The mechanism is studied through both 18O‐crossover experiments as well as quantum chemical calculations. This redox‐neutral transformation provides an unconventional synthetic approach to para‐aminophenols.

  DOI：

  10.1002/anie.202100801

文献信息

• New Analgesics Synthetically Derived from the Paracetamol Metabolite <i>N</i>-(4-Hydroxyphenyl)-(5<i>Z</i>,8<i>Z</i>,11<i>Z</i>,14<i>Z</i>)-icosatetra-5,8,11,14-enamide
  作者：Christian Sinning、Bernhard Watzer、Ovidiu Coste、Rolf M. Nüsing、Ingo Ott、Alessia Ligresti、Vincenzo Di Marzo、Peter Imming

  DOI：10.1021/jm800807k

  日期：2008.12.25

  N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide (AM404) is a metabolite of the well-known analgesic paracetamol. AM404 inhibits endocannabinoid cellular uptake, binds weakly to CB1 and CB2 cannabinoid receptors, and is formed by fatty acid amide hydrolase (FAAH) in vivo. We prepared three derivatives of this new (endo)cannabinoid using bioisosteric replacement (1), homology (2), and derivatization (3)

  N-（4-羟基苯基）-（5Z，8Z，11Z，14Z）-二十碳五，8,11,14-酰胺（AM404）是众所周知的止痛药扑热息痛的代谢产物。AM404抑制内源性大麻素的细胞摄取，与CB1和CB2大麻素受体弱结合，并由体内的脂肪酸酰胺水解酶（FAAH）形成。我们使用AM404中4-氨基苯酚部分的生物立体置换（1），同源性（2）和衍生化（3），制备了这种新的（内切）大麻素的三种衍生物，并针对CB1，CB2和FAAH进行了测试。我们发现对两种大麻素受体的亲和力等于或大于AM404。从C20到C2的酰基链缩短导致了三个新的扑热息痛类似物：N-（1H-吲唑-5-基）乙酰胺（5），N-（4-羟基苄基）乙酰胺（6）和N-（4-羟基-3-甲氧基苯基）乙酰胺（7）。同样，分别针对CB1，CB2、5、6和7进行了测试，和FAAH，没有明显的活动。但是，在全血测定中，5和7表现得像环氧合酶抑制剂。最后，在小鼠福尔马林测试中，5（50
• N-Aryl-N-phenoxy-alkyl-piperazine compounds useful in decreasing
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04413006A1

  公开（公告）日：1983-11-01

  A piperazine derivative of the formula: ##STR1## wherein R.sup.1 is hydrogen, alkyl (C.sub.1-8), alkyl (C.sub.1-4)-sulfonyl or an acyl group of the formula: R.sup.3 CO--(wherein R.sup.3 is hydrogen, alkyl (C.sub.1-7), halogenoalkyl (C.sub.1-4), alkoxy (C.sub.1-4)-carbonyl-alkyl (C.sub.1-4), cycloalkyl (C.sub.3-6), alkenyl (C.sub.2-5), alkoxy (C.sub.1-4), amino, alkyl (C.sub.1-4)-amino or anilino), R.sup.2 is hydrogen, alkyl (C.sub.1-4), alkoxy (C.sub.1-4)-carbonyl-alkyl (C.sub.1-4), carboxy-alkyl (C.sub.1-4), alkenyl (C.sub.2-5) or alkyl (C.sub.1-4)-sulfonyl, or R.sup.1 and R.sup.2 are combined together to form succinyl group, Ring A is phenyl, alkyl (C.sub.1-4)-phenyl or halogenophenyl, and n is an integer of 2 to 6, or a pharmaceutically acceptable acid addition salt thereof. The piperazine derivative (I) has an intracranial pressure-lowering activity. Said derivative also has a depressing effect on central nervous system.

  一种化学式为：##STR1##的哌嗪衍生物，其中R.sup.1为氢、烷基（C.sub.1-8）、烷基（C.sub.1-4）-磺酰基或化学式为R.sup.3 CO-的酰基（其中R.sup.3为氢、烷基（C.sub.1-7）、卤代烷基（C.sub.1-4）、烷氧基（C.sub.1-4）-羰基-烷基（C.sub.1-4）、环烷基（C.sub.3-6）、烯基（C.sub.2-5）、烷氧基（C.sub.1-4）、氨基、烷基（C.sub.1-4）-氨基或苯胺基），R.sup.2为氢、烷基（C.sub.1-4）、烷氧基（C.sub.1-4）-羰基-烷基（C.sub.1-4）、羧基-烷基（C.sub.1-4）、烯基（C.sub.2-5）或烷基（C.sub.1-4）-磺酰基，或R.sup.1和R.sup.2结合形成琥珀酰基，环A为苯基、烷基（C.sub.1-4）-苯基或卤代苯基，n为2至6的整数，或其药学上可接受的酸盐。该哌嗪衍生物（I）具有降低颅内压的活性。该衍生物还对中枢神经系统具有抑制作用。
• PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES
  申请人：Johnson Matthey Public Limited Company

  公开号：US20150361099A1

  公开（公告）日：2015-12-17

  Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R 1 and R 2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR 3 R 4 , OR 5 , or SR 5 , where R 3 and R 4 are individually selected from acyl or sulfonyl, and where R 5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.

  用于制备通式(I)和(VII)中所示的烷基化芳基哌嗪和烷基化芳基哌啶化合物的新工艺和中间体，其中，R1和R2分别选择自氢、烷基、取代基或烷基；n=0、1或2；Y=NR3R4、OR5或SR5，其中R3和R4分别选择自酰基或磺酰基，R5是芳基或杂芳基，或杂环烷基；Ar是芳基、杂芳基或杂环烷基。
• Synthesis, biological evaluation and mechanism study of a class of cyclic combretastatin A-4 analogues as novel antitumour agents
  作者：Jun Yan、Yanqing Pang、Jie Chen、Jianfei Sheng、Jinhui Hu、Ling Huang、Xingshu Li

  DOI：10.1039/c5ra19270f

  日期：——

  In the search for novel antitumor agents, a series of cyclicCA-4analogues bearing amide group, A–B or B–C ring condensation, and CC or CN bond in the B ring were designed, synthesized and identified as microtubule inhibitors.

  在寻找新型抗肿瘤药物的过程中，设计、合成并鉴定了一系列带有酰胺基团、A-B或B-C环缩合以及B环中的C=C或C=N键的环状CA-4类似物，这些类似物被确认为微管抑制剂。
• AROMA COMPOSITIONS OF ALKAMIDES WITH HESPERETIN AND/OR 4-HYDROXYDIHYDROCHALCONES AND SALTS THEREOF FOR ENHANCING SWEET SENSORY IMPRESSIONS
  申请人：Ley Jakob

  公开号：US20080242740A1

  公开（公告）日：2008-10-02

  The invention primarily relates to aroma compositions of (i) certain saliva-stimulating alkamides having a tingling, pungent and/or hot flavor (such as for example pellitorines, spilanthol) with (ii) hesperetin (5,7-dihydroxy-3-(3-hydroxy-4-methoxyphenyl)-chroman-4-one) or the enantiomers and/or salts thereof and/or (iii) 4-hydroxydihydrochalcones (3-(4-hydroxyphenyl)-1-phenylpropan-1-ones) and/or the salts thereof, the use thereof to enhance the sweet flavor of sweet-tasting substances or the sweet odor impression of aroma substances which give rise to a sweet odor impression, but in particular to enhance the sweet initial flavor or odor (initial sweetness). The invention thus relates to the use of said aroma compositions as general sweetness enhancers and enhancers of initial sweetness. The invention further relates to certain preparations which contain an effective amount of said aroma compositions of (i) alkamides (such as in particular pellitorines, spilanthol) with (ii) hesperetin or the enantiomers and/or salts thereof and/or (iii) 4-hydroxydihydrochalcones and/or the salts thereof and methods for enhancing the sweet flavor or initial sweetness of a sweet-tasting substance or the sweet odor impression or initial sweetness of an aroma substance which gives rise to a sweet odor impression. The invention also relates to the use of certain alkamides (i) to enhance the initial sweetness of a preparation comprising (ii) hesperetin or the enantiomers and/or salts thereof and/or (iii) 4-hydroxydihydrochalcones and/or the salts thereof and (b) sweet-tasting substances and/or (c) aroma substances which give rise to a sweet odor impression.

  该发明主要涉及具有刺激唾液分泌的辣味、刺激性和/或辛辣风味的某些唾液激发烷酰胺（例如佩利托林、斯皮兰托尔）与（ii）橙皮素（5,7-二羟基-3-(3-羟基-4-甲氧基苯基)-4-羟基-香豆素）或其对映体和/或盐以及（iii）4-羟基二氢黄烷酮（3-(4-羟基苯基)-1-苯基丙酮）和/或其盐的香气组合物，其用途是增强甜味物质的甜味或产生甜味印象的香料物质的甜味印象，尤其是增强甜味的初始风味或香气（初始甜味）。该发明因此涉及将所述香气组合物用作一般甜味增强剂和初始甜味增强剂。该发明还涉及含有有效量所述香气组合物的某些配方（i）烷酰胺（例如特别是佩利托林、斯皮兰托尔）与（ii）橙皮素或其对映体和/或盐以及（iii）4-羟基二氢黄烷酮和/或其盐的方法，用于增强甜味物质的甜味或初始甜味或产生甜味印象的香料物质的甜味印象或初始甜味。该发明还涉及使用某些烷酰胺（i）来增强含有（ii）橙皮素或其对映体和/或盐以及（iii）4-羟基二氢黄烷酮和/或其盐的配方的初始甜味以及（b）甜味物质和/或（c）产生甜味印象的香料物质的初始甜味。